Shots:

• Gilead collaborates with Novo for the onset of a clinical trial combining its Firsocostat and Cilofexor with Novo’s Semaglutide for the treatment of patients with Nonalcoholic Steatohepatitis (NASH)
• The focus of the collaboration is to combine Gilead and Novo’s expertise for the enhancement of research capabilities and approaches developing novel therapies in NASH
• Semaglutide is a long-acting GLP-1 analogue administered qd to treat non-alcoholic fatty liver disease (NASH). Cilofexor and Firsocostat is a FXR agonist and ACC inhibitor respectively evaluated in P-II targeted for NASH

Click here to read full press release/ article

Ref: Gilead | Image: Gilead